Table 3 In vivo antileukaemic effect of ssHHT
Patient no. | Dose (mg m−2) | Blood blast clearance | Bone marrow D10 | Blood/bm at the end of cytopaenia | Result of treatment |
|---|---|---|---|---|---|
1 | 0.5 | D8 | 94% blasts | Leukaemic | Blood blast clearance |
2 | 0.5 | No clearance | Not done | Leukaemic | No effect |
3 | 0.5 | Not evaluable | Not done | Leukaemic | No effect |
4 | 3 | D7 | 74% blasts | Leukaemic | Blood blast clearance |
6 | 3 | Not evaluable | 63% blasts | Leukaemic | No effect |
7 | 3 | D4 | Clearance | Death | Blood and bm clearance |
8 | 5 | D6 | 70% blasts | Leukaemic | Blood blast clearance |
9 | 5 | D11 | Clearance | 15% in bm | Blood and bm clearance |
10 | 5 | D7 | Not done | Death | Blood blast clearance |
11 | 5 | Not evaluable | 76% blasts | 18% in bm | Reduction of bone marrow blasts |
12 | 5 | Not evaluable | 25% blasts | Leukaemic | No effect |
13 | 5 | D3 | Clearance | Aplastic at D36 | Blood and bm clearance |
14 | 5 | D5 | Clearance | 4% in bm | CR (4 months) |
15 | 5 | D4 | Not done | 4% in bm | CR (3 months) |
16 | 5 | D6 | 41% blasts | 42% in bm | Blood blast clearance |
17 | 5 | Not evaluable | 12% blasts | 5.5% in bm | Blood and bm clearance |
18 | 5 | D7 | Clearance | 7.5% in bm | Return to CMML (6 months) |
19 | 5 | D6 | Not done | Aplastic at D38 | Blood and bm clearance |
